TMEM192

Across TCGA pan-cancer cohorts, TMEM192 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM192 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMEM192 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM192 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where TMEM192 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.707	0.921	<.001	34	view →
CCRCC	OS	Tertile	II,III,IV	0.959	0.278	.024	8	view →
PDAC	OS	Tertile	III,IV	0.951	0.432	.004	6	view →
LUAD	OS	Quartile	II,III,IV	0.651	0.300	.015	4	view →
UCEC	DFS	Tertile	All	0.851	1.000	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM192–LSCC (OS)

Open the LSCC breakdown →